Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
October 17, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
October 15, 2024 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Genomic Services Market Size to Reach USD 17.5 Billion by 2032 - SNS Insider
October 11, 2024 09:00 ET
|
SNS Insider pvt ltd
Pune, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Global Genomics Services Market Size Analysis: According to SNS Insider, The Genomics Services Market was valued at USD 6.3 billion in 2023 and is...
Nucleic Acid Therapeutics CDMO Industry Outlook, 2024-2030 - Increasing Demand for One-Stop-Shop CDMOs and Growing FDIs in Nucleic Acid Therapeutics
October 10, 2024 12:30 ET
|
Research and Markets
Dublin, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering.The...
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
October 10, 2024 07:00 ET
|
Ocugen
MALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Huntingtons Disease Treatment Market to hit USD 2.5 billion by 2032, says Global Market Insights Inc.
October 10, 2024 04:30 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Huntingtons Disease Treatment Market size was valued at USD 457.5 million in 2023, with a projected CAGR of 20.8% over 2024-2032. This...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 09, 2024 07:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 09, 2024 02:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Somagenetix AG secures CHF 10 million in Series A financing to advance lentiviral gene therapy for Chronic Granulomatous Disease (CGD)
October 08, 2024 04:00 ET
|
Somagenetix AG
ZURICH, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its...
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
October 02, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...